No Data
No Data
Zhaoke Ophthalmology Completes Last Patient Visit for Trial of Macular Degeneration Drug
Chow's Ophthalmology-B (06622.HK): The final visit of the last patient in the TAB014 Phase III clinical trial was completed in China.
Glory9thdayTheMeanwhile,ZodiacEye-C(06622.HK)announced that TAB014(oneofthecompany'scorecandidateproperties)hascompletedthelastvisitforthelastpatientinPhaseIIIclinicaltrialfortreatingwet(neovascular)age-relatedmaculardegeneration('wAMD')onSeptember20,2024.Accordingtothedisclosure,TAB014PhaseIIIclinicaltrialisrandomized,double-blind,andnon-inferioritystudy.Theprimaryobjectiveofthestudyistoevaluate the best correction of the group receiving TAB014 treatment compared to the group receiving Lucentis treatment at week 52.
ZHAOKE OPHTH-B: 2024 Interim Report
Zhaoke Ophthalmology Glaucoma Eye Drops Get Marketing Approval; Shares Rise 3%
Chokesee Eye Care-B (06622.HK): Bemei Prostaglandin Eye Drops (Jingbeiqing) approved by the National Medical Products Administration for listing.
Gelonghui, September 20th | Mega Medical Ophthalmology-B (06622.HK) announced that the company's independently developed anti-glaucoma pharmaceutical Beimei Latanoprost Eye Drops (Crystal Bear Clear) has been approved for marketing by the National Medical Products Administration ("NMPA"). According to the disclosure, Beimei Latanoprost Eye Drops (Crystal Bear Clear) is China's first single-dose Latanoprost eye drops without preservatives, used to reduce intraocular pressure in patients with angle-closure glaucoma and high ocular pressure. This pharmaceutical does not contain preservatives, avoiding eye surface damage in glaucoma patients caused by long-term use of preservative-containing medications. At the same time, this medication also helps improve patients
Express News | Zhaoke Ophthalmology Ltd - Marketing Authorization for Bimatoprost Eye Drop (®) Obtained From Nmpa
No Data
No Data